Literature DB >> 1548289

Monoclonal antibodies against a human gastric cancer cell line with lung metastatic potential in nude mice define antigens with different expression between the primary and metastatic liver lesions.

S Hokita1, S Takao, T Muramatsu, H Shimazu.   

Abstract

SCK-29 is a tumor cell line derived from human gastric adenocarcinoma with the feature of producing lung metastases when xenografted in nude mice. Monoclonal antibodies were produced against SCK-29 tumor cells or their glycoproteins prepared by affinity chromatography on a lectin-agarose column. Five antigens defined by the monoclonal antibodies MG-1 to MG-5 were expressed in a large number of gastric or colonic adenocarcinomas. Among the antigens, MG-1 and MG-3 proved to be tumor-associated, since they were detected only occasionally in normal tissues. MG-5 antigen was often detected in normal gastric mucosa but not in other tissues. The degree of expression of MG-1. MG-3 and MG-5 antigens differed considerably in metastatic lesions. In metastatic liver lesions of gastric adenocarcinoma, expression of these MG antigens was less marked than in primary tumors. MG-1 and MG-3 antigens were abolished by neuraminidase digestion and periodate oxidation. MG-5 antigen was likely to be a protein antigen, since it was resistant to neuraminidase digestion and to periodate oxidation but was sensitive to protease digestion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548289     DOI: 10.1007/bf01410139

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.

Authors:  S D Hoff; Y Matsushita; D M Ota; K R Cleary; T Yamori; S Hakomori; T Irimura
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

2.  Distribution of a tumor cell surface protein common to several murine lung carcinomas.

Authors:  S J Kennel; P K Lankford; L J Foote; F S Tsakeres; L M Adams; R L Ullrich
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Part I. Clinical classification. Japanese Research Society for Cancer of the Colon and Rectum.

Authors: 
Journal:  Jpn J Surg       Date:  1983-11

5.  Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein.

Authors:  P Maimonis; D F Hayes; C O'Hara; D Kufe
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

6.  Analysis of antigenic expression by primary and autologous metastatic human sarcomas using murine monoclonal antibodies.

Authors:  J A Roth; C Restrepo; P Scuderi; R W Baldwin; C M Reichert; S Hosoi
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

7.  Cell surface glycoproteins of 13762NF mammary adenocarcinoma clones of differing metastatic potentials.

Authors:  P A Steck; G L Nicolson
Journal:  Exp Cell Res       Date:  1983-09       Impact factor: 3.905

8.  Comparison of the specificities of laminin, thrombospondin, and von Willebrand factor for binding to sulfated glycolipids.

Authors:  D D Roberts; C N Rao; L A Liotta; H R Gralnick; V Ginsburg
Journal:  J Biol Chem       Date:  1986-05-25       Impact factor: 5.157

9.  Cloning of a lymphocyte homing receptor reveals a lectin domain.

Authors:  L A Lasky; M S Singer; T A Yednock; D Dowbenko; C Fennie; H Rodriguez; T Nguyen; S Stachel; S D Rosen
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

10.  Tumorigenicity, invasion, and metastasis of human gastric cancer in nude mice.

Authors:  S Takao; H Shimazu; S Maenohara; S Hokita; T Aikou
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.